secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001437749-26-000694
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex advances diabetes gene therapy GPX-002 into T2D preclinical studies, plans FDA meeting Q1 2026
--------------------------------------------------------------------------------

- Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.
- Submitted meeting request to FDA for Q1 2026 to discuss IND-enabling studies for GPX-002.
- Transferred GPX-002 manufacturing to experienced CDMO; plans clinical-scale cGMP production.
- Continuing construct optimization for second-generation GPX-002 using non-viral lipid nanoparticle delivery.
- Toxicology studies to follow FDA interaction; data expected to enable IND filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926000694/0001437749-26-000694-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926000694/gnpx20260105_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-000694

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer